Topic: rheumatoid arthritis
The data suggest filgotinib is safe and as effective as JAK rivals including AbbVie’s upadacitinib, setting the stage for a four-way commercial scrap.
The past week’s biotech news included insight into how ApoE4 raises Alzheimer’s risk and a peptide vaccine for broad flu protection.
Gilead is eagerly awaiting phase 3 data for its rheumatoid arthritis drug filgotinib that could be an antidote for the biotech’s hepatitis C hangover.
Two new studies suggest that blocking the cytokine IL-1 with a rheumatoid arthritis drug could treat neurological side effects of CAR-T treatments.
The alliance taps into Verily’s work to stratify and analyze white blood cells—and the data abilities come from being part of the same firm as Google.
The expert panel voted 10-5 in favor of the 2-mg dose but flipped those numbers to vote 10-5 against the 4-mg dose.
Eli Lilly and Incyte’s second attempt to get U.S. approval of rheumatoid arthritis drug baricitinib may be scuppered again by FDA concerns on safety.
A PureTech startup is developing an immune-responsive hydrogel that releases a corticosteroid into arthritic joints based on their level of inflammation.
Evobrutinib cut gadolinium-enhancing T1 lesions by more than placebo, but Merck has yet to quantify the difference or say if it beat Tecfidera.
The past week ushered in news about a toxin in scorpion venom that may relieve RA and a skin bacterium with anti-cancer powers.